Brett White

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Cooley advised SCYNEXIS on its exclusive license agreement with GSK for Brexafemme.

Cooley advised CymaBay Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need, on its $97.7 million follow-on offering. Partner Matthew Hemington led the Cooley team.

Cooley advised the underwriters on Zymeworks’ $115.0 million follow-on public offering of 11,035,000 common shares at a price to the public of $8.00 per share and pre-funded warrants to purchase 3,340,000 common shares at a price to the public of $7.9999 per pre-funded warrant. This includes 1,875,000 shares issued upon the exercise in full of the underwriters’ option to purchase additional shares. Zymeworks is a clinical-stage biopharmaceutical company developing and commercializing of next-generation multifunctional biotherapeutics. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Cooley advised Vera Therapeutics on its $86 million follow-on offering of 55,742,026 shares of Class A common stock at a price to the public of $15.00 per share. Vera is a late-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunological diseases. Jodie Bourdet, Brett White and Alexa Ekman led the Cooley team.